An interferon-beta blocker improved dermatomyositis fast, in small phase 2 trials

Dazukibart, an experimental antibody that blocks interferon-beta, improved the skin and muscle symptoms of dermatomyositis within weeks and sustained that benefit for nearly two years in phase 2 testing [s1][s2]. The results are genuinely promising, but they come from very small, manufacturer-run trials — 57 patients in the main skin group and 18 in the muscle group — and the investigators themselves say a properly powered phase 3 study is needed before the drug's effect can be considered established [s1].

Dermatomyositis is a rare autoimmune disease that inflames skin and muscle, producing rashes, weakness and, in some patients, serious internal-organ involvement [s1]. Existing treatments — steroids and broad immunosuppressants — often work incompletely and carry their own toxicity [s1]. A growing body of work implicates type I interferon signalling, and interferon-beta in particular, in driving the disease, which is the rationale for dazukibart, a monoclonal antibody that neutralises interferon-beta specifically rather than suppressing the immune system broadly [s1]. Both trials were sponsored by Pfizer, the drug's developer, and several authors are company employees [s1][s2].

How fast it worked

The core study (NCT03181893) was a double-blind, randomised, placebo-controlled phase 2 trial in which adults received placebo or dazukibart (150 mg or 600 mg) every four weeks [s1]. The 2026 analysis looked specifically at how quickly the drug acted, at weeks 1, 4 and 8 [s1]. In the skin-predominant group (57 patients), the standard skin-disease score (CDASI-A) improved significantly by week 4 — a placebo-adjusted difference of -10.5 points on 150 mg (p=0.0006) and -9.7 on 600 mg (p=0.0004) — and itch improved as early as week 1 on the higher dose (a -2.0-point difference on the 5D-itch scale; p=0.0359) [s1]. By week 4, a clinically meaningful skin response (at least a 40% fall in CDASI-A) had been reached by 53.3% of patients on 150 mg and 42.9% on 600 mg, against 7.7% on placebo [s1].

The muscle-predominant group was too small (18 patients) to test for statistical significance, but showed the same direction: creatine kinase, a muscle-damage marker, fell significantly by week 4 (p=0.0445), and by week 4, 77.8% of patients on 600 mg reached at least minimal improvement on the composite myositis response score versus 66.7% on placebo [s1]. Speed matters clinically in dermatomyositis, where active muscle disease can cause lasting damage, so a response within a month is a meaningful signal — with the heavy caveat that the muscle cohort is far too small to rely on [s1].

Whether it lasted

The second 2026 report combined the 24-week double-blind study with a 52-week open-label extension and a 16-week off-treatment follow-up, for up to 92 weeks of data [s2]. The number of patients carried through is small — 9 in the skin cohort, 15 in the muscle cohort — and everyone received the 600 mg dose in the extension, so there is no longer a placebo comparison [s2]. Within those limits, the improvements held: at week 76 the skin score's median change from baseline was -24.0 points in the skin cohort, and adverse events were mostly mild (55%) or moderate (38%), with no treatment-related serious events and no discontinuations for toxicity [s2]. Gains persisted through the 16-week period after treatment stopped [s2].

Why it matters, and what it doesn't yet show

Targeting interferon-beta specifically is a more precise approach than the broad immunosuppression dermatomyositis patients usually receive, and the early, consistent signal across skin and muscle is a real reason to run a larger trial [s1]. But the honest accounting is that this is proof-of-concept evidence: small samples, one manufacturer's trial programme, an uncontrolled extension, and a patient population that was 96% White, which limits how far the results generalise [s2]. None of that is a mark against the drug — it is the ordinary state of phase 2 evidence, and the sponsors say as much [s1]. Health Newspapers has covered a different approach in the same disease family, where adding immunoglobulin to steroids helped newly diagnosed myositis, a broader intervention than blocking a single cytokine.

What to watch

The decisive test is the phase 3 trial the investigators call for: larger, adequately powered in the muscle-predominant group, and ideally more diverse [s1]. Until then, the case for dazukibart rests on small numbers that point the same way — encouraging, not conclusive [s1][s2].

This article describes research and is not medical advice or a treatment recommendation.

Sources

• Rapid onset of response in adults with dermatomyositis receiving dazukibart: a phase 2 study — Clinical, Cosmetic and Investigational Dermatology, 3 June 2026
• Long-term safety and efficacy of dazukibart in dermatomyositis: combined phase II results — The Journal of Rheumatology, 1 August 2026